Comparing Iovera cold nerve‑freezing versus radiofrequency heat treatment for chronic lumbar facet-related low back pain
Official title: A Prospective, Randomized, Assessor Blind, Active-controlled, Single-center Study to Evaluate the Efficacy of Iovera Lumbar Medial Branch Cryoneurolysis Versus Radiofrequency Ablation for the Treatment of Facet-mediated Chronic Low Back Pain
Run by Montefiore Medical Center · NCT07214844 · Data updated 2026-11-12
This test compares Iovera's cold-based nerve-freezing with standard radiofrequency heat treatment to see which reduces long-term low back pain in adults with suspected facet-joint pain.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 110 (estimated) |
| Sponsor | Montefiore Medical Center Academic / other |
| Locations | 1 site (The Bronx, New York) |
| Status | Recruiting |
| Started | April 16, 2026 |
| Main results expected | May 2028 |
| Study ends | May 2028 |
| Registry record updated | June 17, 2026 |
| Trial ID | NCT07214844 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with chronic (≥3 months), moderate-to-severe axial low back pain thought to be facet-mediated who achieved ≥80% relief from two diagnostic medial branch blocks and have failed ≥3 months of conservative care.
✕Probably not a fit
Patients whose pain is not facet-joint related, who have low pain scores (<5), or who did not have positive diagnostic medial branch blocks are unlikely to receive benefit from these procedures.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized study assigns adults with chronic, moderate-to-severe lumbar facet-mediated back pain to receive either Iovera medial branch cryoneurolysis or standard radiofrequency ablation. Eligible participants must have had two diagnostic medial branch blocks with at least 80% temporary pain relief and have failed at least three months of conservative therapy. Investigators will track pain, function, medication use, safety, quality of life, and patient satisfaction over about 12 months, with each participant in the study for roughly 14 months. An adaptive design includes a blinded interim analysis after approximately 56 subjects to reassess sample size assumptions.
Why it matters
Potential benefit: If successful, the Iovera approach could provide longer or comparable pain relief with a different side-effect profile and broaden non-surgical options for facet-mediated chronic low back pain.
How similar studies have gone: Radiofrequency ablation is an established treatment for facet-mediated back pain, while medial branch cryoneurolysis (Iovera) has shown promising but limited comparative evidence to date.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:
Subjects must meet all of the following inclusion criteria to be eligible for participation:
* Subjects at least 18 years of age at Screening
* Primary complaint of axial low-back pain suggestive of bilateral facet joint involvement (i.e., facet mediated CLBP) by evidence of provocative testing (e.g., axial loading, paraspinal tenderness)
* Low back pain is chronic (i.e., ≥ 3 months' duration)
* Low back pain is moderate to severe (score of ≥ 5 to ≤ 9) on the 0 to 10 NRS at Screening
* Low back pain causes functional impairment (≥ 30% on ODI) at Screening
* Successful trial of two diagnostic medial branch blocks consisting of two positive blocks with local anesthetic only (i.e., no steroids) that results in at least 80% relief of primary (index) pain for the duration of the local anesthetic used
* Failure of at least three months of conservative non-operative therapy (e.g., physical therapy, chiropractic care, sleep hygiene, weight loss, spinal injections, NSAIDs, physician-directed exercise program or other appropriate analgesics)
* Able to provide informed consent, adhere to the study visit schedule, and complete all study assessment
Exclusion Criteria:
Subjects who meet any of the following exclusion criteria will not be eligible for participation in this study:
* Active workers' compensation, personal injury, Social Security disability insurance (SSDI), or other litigation/compensation related to the spine
* Serious spinal disorders (verified on magnetic resonance imaging (MRI)) that may impact outcomes, including any of the following:
1. Suspected cauda equina syndrome (e.g., bowel/bladder dysfunction)
2. Infection
3. Tumor
4. Traumatic fracture
5. Systemic inflammatory spondyloarthropathy
6. Lumbar radiculopathy/radiculitis (i.e., root irritation and deficit)
7. Neurogenic claudication Prior lumbar spinal fusion surgery at the intended treatment levels
* Comorbidity that, in the judgment of the Investigator, may affect the subject's ability to participate in the study including lumbar radiculopathy and neuropathic pain disorder
* Currently pregnant, nursing, or planning to become pregnant during the study
* Known contraindication to study device, including any of the following:
1. Cryoglobulinemia
2. Paroxysmal cold hemoglobinuria
3. Cold urticaria
4. Raynaud's disease
5. Open and/or infected wounds at or near the treatment site
6. Coagulopathy
* Severe chronic pain disorder that in the opinion of the investigator may impact study outcomes
* Presence of any of the following:
1. Spinal neurostimulator
2. Intrathecal analgesic drug pump
3. Cardiac implantable device
* Current manifestation of poorly controlled mental illness or catastrophizing that in the opinion of the investigator may meaningfully impact treatment outcomes, including any of the following:
1. Mood disorder (e.g., depression, bipolar)
Patient Health Questionnaire (PHQ-9) ≥ 12 at Screening
2. Psychotic disorder (e.g., schizophrenia)
3. Catastrophizing
Patient Catastrophizing Scale (PCS) score \> 30 at Screening
* Subject received other spine intervention/therapies in the 30 days prior to block administration (e.g., spinal injections, minimally invasive therapies, surgical therapies) at the intended lumbar treatment levels
* Subject received radiofrequency ablation in the low back region ≤ 6 months before study enrollment at the intended lumbar treatment levels
* Pain relief following diagnostic medial branch blocks lasted longer than the duration of the local anesthetic used (i.e., \> 24 hours)
1. History, suspicion, or clinical manifestation of:
2. Alcohol abuse or dependence
3. Illicit drug use
* Opioid abuse or dependence (≥40 mg medication PO/day in past 30 days)
* Given the COVID-19 pandemic, the subject must be medically fit/cleared for surgery by the investigator. If there is a concern about a subject's recent or potential exposure to COVID-19, or if the subject is not medically fit/cleared for surgery due to suspected COVID-19 illness/symptoms (or other serious illness), the subject must be excluded.
Where it's running
-
Montefiore Multidisciplinary Pain Program
The Bronx, New York, United States Recruiting
Study contacts
- Principal investigator: Karina Gritsenko, MD — Montefiore Medical Center
- Study coordinator: Karina Gritsenko, MD
- Email: kgritsen@montefiore.org
- Phone: 609-369-0344
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Combined strength, flexibility and aerobic exercise program for chronic low back pain
This program will test whether an 8-week combined exercise plan—running or swimming/cycling plus progressive strength and flexibility work—helps adults aged 18–45 with chronic low back pain reduce pain and improve function compared with their usual exercise.
-
Effects of respiratory muscle training on chronic low back pain
This study is testing if adding breathing exercises to physical therapy can help people with chronic low back pain feel better and improve their daily life.
-
Ultrasound-Guided Thoracolumbar Fascia Injection for Chronic Low Back Pain in Type 2 Diabetes
This trial tests whether an ultrasound-guided injection into the thoracolumbar fascia, added to standard care, helps reduce chronic low back pain in adults with type 2 diabetes.
-
Subcutaneous Fat, Back Muscles, and Spine Shape in Back Pain Patients
This study tests whether body fat under the skin and features of back muscles and spine joints are linked to lumbar facet joint degeneration in adults with chronic low back pain.
-
See if serum BDNF levels relate to outcomes in chronic low back pain
This study tests whether blood BDNF levels can help predict how patients with chronic low back pain will do over time.
-
Correlating periostin levels with spinal degeneration in back pain
This study tests whether periostin levels in the intervertebral disc relate to the severity of disc degeneration in people with chronic low back pain and spinal stenosis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.